question is provided by recent results from Vadim Ara profound circling toward the side with RGS9-2 overexpression when the rats were administered dopamine shavsky and colleagues (Martemyanov et al., 2003) . They noticed sequence similarity between part of the receptor (specifically D2) agonists. This circling behavior is thought to arise from an imbalance in dopaminergic C-terminal tail of RGS9-2 and PDE ␥ and decided to test the hypothesis that this domain increases RGS9-2 GAP signaling, consistent with the overexpression of RGS9-2 decreasing the sensitivity to dopamine. Rats overexactivity, analogous to the effect of PDE ␥ on RGS9-1. The results suggest that indeed it does. In the presence pressing RGS9-2 bilaterally showed less sensitivity to moderate doses of cocaine, as assayed by a reduction in of the PDE ␥ -like stretch in its C-terminal tail, RGS9-2 displays high GAP activity, just as RGS9-1 does in the cocaine-induced locomotor activity. Conversely, RGS9 knockout mice show enhanced locomotor activity, presence of PDE ␥ . Addition of PDE ␥ does not stimulate GAP activity further, but instead inhibits it, presumably greater sensitization, and greater place conditioning in response to cocaine. Together, these results are consisby competing with RGS9-2's C-terminal tail. When GAP activity was tested for a truncated form of RGS9-2 lacktent with the notion that RGS9-2 turns down the response to dopamine in the nucleus accumbens. ing the C-terminal 45 amino acids, including a stretch of six identical to a sequence in PDE ␥ , the activity was
The results from Nestler's group imply a role for RGS9-2 in signaling from D2 dopamine receptors, but significantly reduced. Taken together, these observations seem to be yet another example of a principle it is too early to say whether the effects they observe are the result of direct action on G proteins activated pointed out in genome-scale studies from David Eisenberg and colleagues: pairs of proteins homologous to directly by D2 receptors or the result of a more complex network of interactions (Figure 2 ). Because RGS9-2 does pairs of domains found covalently attached in multidomain proteins are very often functional interaction partnot need to rely on an effector molecule to enhance GTP hydrolysis (see above), it remains unknown how ners (Marcotte et al., 1999) . As pointed out by Martemyanov et al., one function of such interaction partners can and if the action of RGS9-2 is cascade specific. Answering these questions will require knowing which G probe to act as "affinity adapters" to control specificity of interactions with additional proteins. However, the teins and effectors, operating in response to which G protein-coupled receptors, are regulated by RGS9-2. details of the interactions seem to be somewhat different in the two cases compared here. Six consecutive resiLocalization of RGS9-1 in rod outer segments where dues in PDE ␥ are known by crystallography to contact G ␣ in the G ␣ -RGS-PDE ␥ complex (Slep et al., 2001) , and mutating one of them, Trp70, causes complete loss of the ability to stimulate GAP activity (Slepak et al., 1995) . Changing all six to alanines in RGS9-2 is apparently without effect. In the course of these studies, Martemyanov et al. also found that RGS9-2 is a better GAP for G ␣o than G ␣i1 , as reported previously for RGS9-1 (Hooks et al., 2003) , and found that RGS9-2, like RGS9-1, is an even better GAP for G ␣t . Given that G ␣t and RGS9-2 are not found in the same cell types, it seems likely that localization plays a more important role in determining specificity of action of RGS isoforms on different G proteins than the differences in intrinsic affinity observed.
Important isoforms unilaterally in the nucleus accumbens induced rhodopsin and transducin are found played an important light of the biochemical evidence presented by Martemyanov et al., one might expect that RGS9-1 should role in determining its function. Unfortunately, precise colocalization in striatal neurons has been difficult behave lower affinity for its target (presumably G o ) than RGS9-2, at least in the absence of PDE ␥ . Perhaps the cause the several antibodies used to great effect with RGS9-1 suffer from low specificity and affinity when native substrate for RGS9-2 in these cells is normally a low-affinity interaction, such as that with G ␣i , which applied to RGS9-2 in striatal extracts. Localization is critical because RGS9-2 presumably must be coloMartemeyanov et al. found to be relatively insensitive to both RGS9-1 and RGS9-2. Alternatively, perhaps an calized with the G proteins and effectors it regulates, which in turn are likely colocalized with one or more additional molecule in the G protein/effector complex can serve this affinity adaptor function in the absence specific GPCR. Moreover, it has been reported that RGS9-2 and other R7 RGS proteins can be found in the of the C-terminal tail normally present on RGS9-2. A more mundane explanation may be that the levels of nucleus, but the role of the nuclear pool in G protein signaling is unknown. Although RGS9-2 mRNA has been RGS9-1 were sufficiently higher than normal cellular levels of RGS9-2 to act effectively despite its lower basal identified in medium spiny neurons expressing dopamine D2 receptors, it is also present in an equal fraction activity. The fact that overexpression of RGS4, which shows robust GTPase activity for both Go and Gi, had of cells that express D1 receptors (Rahman et al., 2003) . Medium spiny cells can be roughly divided into two no effect suggests that interactions with other proteins, likely through the non-RGS domains, are important for populations, those that contain substance P and primarily express D1, and those that contain enkephalin and RGS9-2 function. Another puzzle is the role of G ␤5 in the striatum. Striatal primarily express D2. The expression of RGS9 in both of these cell types suggests that its function may not neurons express a short version of this protein, G ␤5S , and although G ␤5S potentiates the effects of RGS9 in be to regulate D2 receptor signaling per se, but to regulate the cascade of some other G protein-coupled recepvitro, efficacy of RGS9-2, presumably due to GAP activity, can be observed in the absence of G ␤5S ( 
